new drug for Parkinson's disease called Azilect (rasagiline)
October 2006
Health Canada has approved a new drug for Parkinson's disease called Azilect (rasagiline).
It's an MAO-B inhibitor...similar to selegiline. It works by blocking the breakdown of dopamine.
Azilect can be used as initial therapy...to improve symptoms in patients with early Parkinson's.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote